Ymir

Ymir Genomics is a private biotechnology company developing non-invasive biomarker discovery tools and diagnostic approaches based on extracellular vesicles and circulating RNA found in biofluids such as urine, blood, saliva, and cerebrospinal fluid. The company focuses on isolating and analyzing exosomal and other extracellular vesicle cargo, including microRNA and proteins, to identify biomarkers relevant to diagnostics, prognosis, and therapeutic targeting. Ymir has highlighted internal and collaborative work in urologic cancers and liver disease, including programs in prostate cancer, bladder cancer, cirrhosis, and hepatocellular carcinoma. Its business appears to center on a proprietary sample-processing and bioinformatics platform rather than a late-stage therapeutic pipeline. The company is headquartered in Cambridge, Massachusetts and remains a small, private, active biotech venture.